Patel Ashna, Kutuzov Mikhail A, Dustin Michael L, van der Merwe P Anton, Dushek Omer
The Sir William Dunn School of Pathology, University of Oxford, Oxford OX1 3RE, UK.
The Kennedy Institute of Rheumatology, University of Oxford, Oxford OX3 7FY, UK.
Immunother Adv. 2024 Jun 19;4(1):ltae004. doi: 10.1093/immadv/ltae004. eCollection 2024.
CD8+ T cells contribute to immune responses by producing cytokines when their T-cell receptors (TCRs) recognise peptide antigens on major-histocompability-complex class I. However, excessive cytokine production can be harmful. For example, cytokine release syndrome is a common toxicity observed in treatments that activate T cells, including chimeric antigen receptor (CAR)-T-cell therapy. While the engagement of costimulatory receptors is well known to enhance cytokine production, we have limited knowledge of their ability to regulate the kinetics of cytokine production by CAR-T cells. Here we compare early (0-12 h) and late (12-20 h) production of IFN-gg, IL-2, and TNF-a production by T cells stimulated via TCR or CARs in the presence or absence ligands for CD2, LFA-1, CD28, CD27, and 4-1BB. For T cells expressing TCRs and 1st-generation CARs, activation by antigen alone was sufficient to stimulate early cytokine production, while co-stimulation by CD2 and 4-1BB was required to maintain late cytokine production. In contrast, T cells expressing 2nd-generation CARs, which have intrinsic costimulatory signalling motifs, produce high levels of cytokines in both early and late periods in the absence of costimulatory receptor ligands. Losing the requirement for costimulation for sustained cytokine production may contribute to the effectiveness and/or toxicity of 2nd-generation CAR-T-cell therapy.
CD8 + T细胞在其T细胞受体(TCR)识别主要组织相容性复合体I类上的肽抗原时,通过产生细胞因子来促进免疫反应。然而,过量产生细胞因子可能有害。例如,细胞因子释放综合征是在激活T细胞的治疗中常见的毒性反应,包括嵌合抗原受体(CAR)-T细胞疗法。虽然共刺激受体的参与众所周知可增强细胞因子的产生,但我们对其调节CAR-T细胞产生细胞因子动力学的能力了解有限。在这里,我们比较了在存在或不存在CD2、LFA-1、CD28、CD27和4-1BB配体的情况下,通过TCR或CAR刺激的T细胞在早期(0 - 12小时)和晚期(12 - 20小时)产生IFN-γ、IL-2和TNF-α的情况。对于表达TCR和第一代CAR的T细胞,仅抗原激活就足以刺激早期细胞因子产生,而CD2和4-1BB的共刺激是维持晚期细胞因子产生所必需的。相比之下,表达具有内在共刺激信号基序的第二代CAR的T细胞,在没有共刺激受体配体的情况下,在早期和晚期都产生高水平的细胞因子。失去持续产生细胞因子对共刺激的需求可能有助于第二代CAR-T细胞疗法的有效性和/或毒性。